IONS · Ionis Pharmaceuticals, Inc.
AI read · Good for IONS
The AI's read
This gives Ionis a stronger chance of receiving later payments from Roche if the drug reaches patients. Results were consistent across the patient groups studied, and no new safety signals appeared. The study is still tracking kidney function for 2 years, and sefaxersen remains experimental. Those steps still matter, but they do not outweigh the strong Phase 3 findings.